 |
22 Diseases |  |
0 Trials |
|
0 Trials |  |
180 News |  |
| «123 |
- oprozomib (ONX 0912) / Amgen
Enrollment change, Trial withdrawal, Trial primary completion date, Combination therapy, Metastases: Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 6, 2015
P1/2, N=0, Withdrawn, Sponsor: Onyx Therapeutics, Inc.
N=140 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Apr 2017 --> Mar 2015
- oprozomib (ONX 0912) / Amgen
Trial completion, Enrollment change, Trial primary completion date: A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Nov 5, 2015
P1/2, N=9, Completed, Sponsor: Onyx Therapeutics, Inc.
N=140 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Apr 2017 --> Mar 2015 Active, not recruiting --> Completed | N=74 --> 9 | Trial primary completion date: Oct 2015 --> Jan 2015
- ||| oprozomib (ONX 0912) / Amgen
Enrollment closed, Combination therapy, Metastases: Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 25, 2015
P1/2, N=140, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Active, not recruiting --> Completed | N=74 --> 9 | Trial primary completion date: Oct 2015 --> Jan 2015 Recruiting --> Active, not recruiting
- ||| oprozomib (ONX 0912) / Amgen
Enrollment closed, Combination therapy: Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jun 25, 2015
P1/2, N=134, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| oprozomib (ONX 0912) / Amgen
Enrollment closed: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 25, 2015
P1/2, N=128, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| oprozomib (ONX 0912) / Amgen
Enrollment closed: Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies (clinicaltrials.gov) - Jun 25, 2015
P1/2, N=364, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- oprozomib (ONX 0912) / Amgen
Enrollment closed, Metastases: A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies (clinicaltrials.gov) - Apr 23, 2015
P1, N=48, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- oprozomib (ONX 0912) / Amgen
Metastases: A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies (clinicaltrials.gov) - Mar 7, 2015
P1, N=48, Recruiting, Sponsor: Onyx Therapeutics, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- ||| oprozomib (ONX 0912) / Amgen
Enrollment closed: A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Feb 6, 2015
P1/2, N=74, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Active, not recruiting
- |||| oprozomib (ONX 0912) / Amgen
Enrollment open, Trial initiation date, Combination therapy, Metastases: Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 5, 2015
P1/2, N=124, Recruiting, Sponsor: Onyx Therapeutics, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Dec 2014
- || oprozomib (ONX 0912) / Amgen
Clinical: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 28, 2015
P1/2, N=128, Recruiting, Sponsor: Onyx Therapeutics, Inc.
Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Dec 2014 Trial primary completion date: Jul 2015 --> Jun 2016
- | oprozomib (ONX 0912) / Amgen
New P1 trial, Metastases: A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies (clinicaltrials.gov) - Sep 19, 2014
P1, N=48, Recruiting, Sponsor: Onyx Therapeutics, Inc.
- ||||| oprozomib (ONX 0912) / Amgen
New P1/2 trial, Combination therapy, Metastases: Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 29, 2014
P1/2, N=124, Not yet recruiting, Sponsor: Onyx Therapeutics, Inc.
- |||| oprozomib (ONX 0912) / Amgen
Clinical: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 3, 2014
P1/2, N=314, Recruiting, Sponsor: Onyx Therapeutics, Inc.
Trial primary completion date: Jul 2015 --> Jun 2016 Active, not recruiting --> Recruiting
- || oprozomib (ONX 0912) / Amgen
Clinical: Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies (clinicaltrials.gov) - Jun 2, 2014
P1/2, N=349, Recruiting, Sponsor: Onyx Therapeutics, Inc.
Active, not recruiting --> Recruiting Trial primary completion date: May 2014 --> May 2016
- ||| oprozomib (ONX 0912) / Amgen
Clinical: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 2, 2014
P1/2, N=314, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Trial primary completion date: May 2014 --> May 2016 Recruiting --> Active, not recruiting
- ||||| oprozomib (ONX 0912) / Amgen
New P1/2 trial: A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Feb 25, 2014
P1/2, N=74, Recruiting, Sponsor: Onyx Therapeutics, Inc.
- ||| oprozomib (ONX 0912) / Amgen
Combination therapy: Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Feb 20, 2014
P1/2, N=118, Recruiting, Sponsor: Onyx Therapeutics, Inc.
Recruiting --> Active, not recruiting N=59 --> 118
- |||| oprozomib (ONX 0912) / Amgen
Combination therapy: Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Dec 10, 2013
P1/2, N=118, Recruiting, Sponsor: Onyx Therapeutics, Inc.
N=59 --> 118 Not yet recruiting --> Recruiting
- ||| oprozomib (ONX 0912) / Amgen
Clinical: Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies (clinicaltrials.gov) - Dec 2, 2013
P1/2, N=349, Recruiting, Sponsor: Onyx Therapeutics, Inc.
Not yet recruiting --> Recruiting N=263 --> 349
- ||||| oprozomib (ONX 0912) / Amgen
New P1 trial: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 1, 2013
P1/2, N=314, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
- | oprozomib (ONX 0912) / Amgen
Trial completion, Metastases: Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors (clinicaltrials.gov) - Dec 1, 2013
P1, N=44, Completed, Sponsor: Onyx Therapeutics, Inc.
N=263 --> 349 Recruiting --> Completed
- ||||| oprozomib (ONX 0912) / Amgen
Combination therapy: Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jun 18, 2013
P1/2, N=118, Recruiting, Sponsor: Onyx Therapeutics, Inc.
- |||| oprozomib (ONX 0912) / Amgen
Clinical: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - May 8, 2013
P1/2, N=128, Recruiting, Sponsor: Onyx Therapeutics, Inc.
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| oprozomib (ONX 0912) / Amgen
Clinical: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 14, 2013
P1/2, N=128, Recruiting, Sponsor: Onyx Therapeutics, Inc.
- |||| oprozomib (ONX 0912) / Amgen
Clinical: Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies (clinicaltrials.gov) - Nov 1, 2012
P1/2, N=349, Recruiting, Sponsor: Onyx Therapeutics, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| oprozomib (ONX 0912) / Amgen
Clinical: Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies (clinicaltrials.gov) - Aug 11, 2011
P1/2, N=349, Recruiting, Sponsor: Onyx Therapeutics, Inc.